Video pitch - https://youtu.be/B3vyCq4DF3g
Everyone should have access to eye care. EyeQue provides the tools for everyone to get glasses online by themselves.
Vision problems are a global challenge. Today more than 2B people are suffering from vision deficiencies, and this number is growing fast.
In the US, 100M people, only a half of the people who need it, get an eye exam every year. But even that is more than a quarter million exams per day.
Some may consider this lucky since the number of eye care providers is not enough to handle this load.
Overall, the US eye exam market is very big with a size figure around $15B.
The main challenges are access and cost. Many people do not have access to an eye doctor or cannot afford one.
Other challenges include the hassle in getting an eye exam and the fact that most people do not consider it a high priority.
EyeQue is here to address all of these issues.
The notion that everyone should have access to eye care stays at the core of the company as it evolved to offer a complete set of innovative vision solutions, including a digital platform, screening devices, and its core technology – refraction measurement devices.
The company has an extensive IP portfolio and received many awards throughout the years.
EyeQue has a very solid stance with regulatory agencies and complies to the highest quality standards.
The company traction has been substantial with over 100,000 users worldwide.
We know our technology works well.
EyeQue is first and foremost a technology company. We developed a digital platform, EyeQue Connect, that allows anyone, from anywhere, at anytime to access eyecare.
The first application allows optical stores to send patient data to eye doctors and receive a prescription for glasses or contacts for the patient. This service is already in use today and is steadily growing.
The second technology element that we developed at EyeQue is our screening devices. These devices bring a virtual environment to perform the most common vision screening tests – the wall chart, color blindness, common eye diseases like cataract, and central vision. The devices attach to a smartphone and provide very fast and accurate measurements either in office or at-home. Patients can take the tests by themselves or be guided by an operator.
EyeQue’s core technology is its refraction technology. We are the only company that has the technology for a self-administered measurement of the numbers in your glasses prescription. The technology is based on an MIT patent, licensed exclusively by EyeQue.
The measurement is done by attaching a device onto a phone screen. If the measured eye is normal, the lines from the screen will go through the device and will overlap at the back of the eye. For an eye that needs glasses, the lines will not. The user can then move the lines on the screen until they do overlap. At that point, the system calculates the value of glasses needed from the new distance on the screen.
This technology already went through preliminary clinical trials, but more importantly, thousands of people have already used it to order glasses online with much success.
EyeQue is looking for an investment to improve our technology and to achieve widespread adoption of our solutions.
We currently have a lot of the necessary components, but we are looking to improve the solutions and distribute them to the masses.
From a technology perspective, we would like to improve our digital platform to become an all-in-one solution for eye care.
This will include expanding the applications and use cases, integrating devices that already exist in the market, and adding artificial intelligence for both customer interaction and data management and analysis.
On the screening front, we would like to add tests to the existing devices as well as integrate additional test like field of view and imaging.
We would like to have a complete solution for performing these tests for both in office or at home.
Refraction measurement is already enabled with our current devices, but we would like to make them easier to use by making the tests faster and integrating AI into the test flow. This will make it much easier to adopt and would potentially even improve the device accuracy. In the office, we would also develop a binocular device that has been clinically proven to allow accurate measurements of young children.
COVID opened the path for anything remote. The future of medicine is telemedicine. It is inevitable that eyecare will be virtual as well. EyeQue has the solutions, and even with a simplistic and conservative revenue model, the financial potential is in the tens of millions or more.
The most important part of the company is its people. EyeQue’s leadership is a great team with vast experience and more importantly, expertise in this field. You will not find a better team for this effort anywhere.
John, our CEO and founder, is a PhD physicist from MIT with over 40 years of experience leading hardware and software businesses.
Nicole has been working in the eyecare industry for more than 20 years and has a vast network of connections in the field. She is the woman of the year in optometry by Vision Monday.
Kathy is an MIT graduate who held many senior roles in finance for over 20 years.
I have a CTO certificate from Berkeley and a PhD in applied physics. I have been leading technology for the past 25 years from defense, semiconductors, consumer products to medical devices.
EyeQue never lacks ideas. We have a very rich roadmap with no technological barriers.
We are looking to raise 5-10 million dollars to allow us to execute our plan of improving our technology and significantly expanding our sales operations.
EyeQue is the only company that has self-refraction technology. We have an ambitious roadmap and the people with the know-how to implement it.
The market is huge and the financial potential is significant.
EyeQue has all the components to truly be a unicorn.